about
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.Long term cerebral and vascular complications after irradiation of the neck in head and neck cancer patients: a prospective cohort study: study rationale and protocol.Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas.Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerPrognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients.Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial.Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review.The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.Progression of carotid intima media thickness after radiotherapy: a long-term prospective cohort study.Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.Tumor volume as a prognostic factor for local control and overall survival in advanced larynx cancer.The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome.Penile sparing surgery for penile cancer-does it affect survival?Prospective cohort study of carotid intima-media thickness after irradiation.An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival.Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube.Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium.Penile cancer stage, survival and body mass index.Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival.Prophylactic pelvic lymph node dissection in patients with penile cancer.Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.Blood and lymphatic microvessel damage in irradiated human skin: The role of TGF-β, endoglin and macrophages.Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.
P50
Q33407669-900D5103-B6EA-4401-9DCA-1E4761A7DBF0Q33437774-5F80C60A-B3B6-481E-85C7-751E9F2E418DQ33440357-67AB8C3F-6CAF-41AF-A5A6-E291F3EE9E5FQ33828776-F4864353-768D-4E7F-93D0-C661ECA22979Q36638185-E62E9646-A0B0-4421-81DC-2338736793FBQ37385251-6444ECD4-C47A-47DD-8CEA-D10700DA4EEFQ37783664-AAA9629F-7A7D-433A-B513-105667E3643FQ37912759-BC51C117-50CC-423B-9C01-631C2509D53BQ38387754-2E82AE05-BE79-4BFE-8C7B-F71012714D3DQ38390826-AAFB8D61-4561-4379-B15F-8CBD1A94CE5DQ38392019-3625DA54-F003-4B68-B067-E7B6B61BF09AQ38639243-1553EEA3-4DFB-459C-A54F-DDFE0DF2BB64Q38767329-D66E641A-0525-435A-8B77-7B415AE142C6Q39085486-2F26FE7A-A720-4C03-BB89-5225DE500D06Q39720317-400388F8-4B18-4CE1-B4DC-207156A5A892Q40234339-461A6EE0-FE8D-48FD-980E-00B25BEF63D7Q40836685-0EEF3208-B709-444C-86EB-C38D340837EEQ40836707-CC7D730E-B804-476E-AFCD-3173590993DFQ41430140-5CEE5F07-24CC-4DFF-B116-33C4743D2BCDQ41547727-06C732DA-4F79-425A-962C-64E30E113FF0Q41547803-DB1D33DD-9699-4D91-8EFF-DC14B7BA2B8DQ42198337-04DB9F59-C9C9-4434-B9AD-C7AD46D6CEC1Q44323530-ED228901-DA87-4778-9658-CE507B040504Q45859873-B29CD687-5068-4A75-BA45-FE1D41CD6CB6Q45994048-F7092999-A251-41C6-BEC9-67B2500EEC11Q46836320-27D8BC83-C687-49DE-92EF-3EC1E6CCE763Q47932143-FD869138-7A4A-42AE-B420-223A16E6249EQ49204891-394A9F24-7CCC-42DF-8FFD-51192A26DF55Q49678698-63336620-48AF-4F15-8565-990300B26D51Q50583680-CE891452-5D51-48AC-9916-90E4530C8AC6Q50591579-A5F1B276-F8EF-4778-A38B-2537FB57A27FQ50598248-EEAA6382-02F3-4015-94F5-55C663B9B772Q50995491-32D7692F-4FF5-45AA-BAD4-2110704949A9Q51588763-22DB0205-F438-4AD7-A76B-CEFF620BFC48Q51796512-B3327F1F-2FA0-48B5-8AF1-C546FC907F9EQ52560949-138A1BE9-239F-4F28-992E-077204F062A0Q52724421-02A8607E-FBBC-467D-AA58-BE6B2EDAAF81Q52727390-6ABDB713-32E1-4B4A-9D3E-DC14DF9AC733Q52918808-EE56034B-06DB-40D8-9C6B-C68C4AD9F11AQ52929887-7D60D0ED-8560-4AF1-B021-3B8F196240CD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Erik van Werkhoven
@ast
Erik van Werkhoven
@en
Erik van Werkhoven
@es
Erik van Werkhoven
@nl
type
label
Erik van Werkhoven
@ast
Erik van Werkhoven
@en
Erik van Werkhoven
@es
Erik van Werkhoven
@nl
prefLabel
Erik van Werkhoven
@ast
Erik van Werkhoven
@en
Erik van Werkhoven
@es
Erik van Werkhoven
@nl
P106
P1153
36338183600
P31
P496
0000-0001-7469-7427